Skip to Content


In the US, Pazopanib (pazopanib systemic) is a member of the drug class VEGF/VEGFR inhibitors and is used to treat Renal Cell Carcinoma and Soft Tissue Sarcoma.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Cytostatic agent

Chemical Name

5-({4-[(2,3-dimetyl-2H-indazol-6-yl)metylamino]pyrimidin-2-yl}amino)-2-metylbenzenesulfonamide (WHO)

Foreign Names

  • Pazopanibum (Latin)
  • Pazopanib (German)
  • Pazopanib (French)
  • Pazopanib (Spanish)

Generic Names

  • Pazopanib (OS: BAN)
  • GW 786034 (IS)
  • UNII-7RN5DR86CK (IS)
  • Pazopanib Hydrochloride (OS: USAN, BANM, JAN)
  • GW786034B (IS)
  • UNII-33Y9ANM545 (IS)

Brand Names

  • Votrient
    Glaxo Group, Lithuania; Glaxo Group, Slovakia; Glaxo Wellcome, Portugal; Glaxo Wellcome, Serbia; GlaxoSmithKline, Indonesia; GlaxoSmithKline, Italy; GSK, Turkey; Novartis Europharm, Slovenia; Wellcome Limited, Bosnia & Herzegowina; Glaxo Group, Austria; Glaxo Group, Greece; Glaxo Group, Hungary; Glaxo Group, Iceland; Glaxo Group, Poland; Glaxo Group, Romania; GlaxoSmithKline, Argentina; GlaxoSmithKline, Australia; GlaxoSmithKline, Canada; GlaxoSmithKline, Chile; GlaxoSmithKline, Colombia; GlaxoSmithKline, Costa Rica; GlaxoSmithKline, Czech Republic; GlaxoSmithKline, Germany; GlaxoSmithKline, Denmark; GlaxoSmithKline, Spain; GlaxoSmithKline, Finland; GlaxoSmithKline, Guatemala; GlaxoSmithKline, Hong Kong; GlaxoSmithKline, Honduras; GlaxoSmithKline, Croatia (Hrvatska); GlaxoSmithKline, Ireland; GlaxoSmithKline, Israel; GlaxoSmithKline, Japan; GlaxoSmithKline, Latvia; GlaxoSmithKline, Mexico; GlaxoSmithKline, Malaysia; GlaxoSmithKline, Netherlands; GlaxoSmithKline, Norway; GlaxoSmithKline, New Zealand; GlaxoSmithKline, Philippines; GlaxoSmithKline, Sweden; GlaxoSmithKline, Singapore; GlaxoSmithKline, El Salvador; GlaxoSmithKline, Thailand; GlaxoSmithKline, United States; GlaxoSmithKline, Vietnam; GlaxoSmithKline UK, United Kingdom; Novartis, Belgium; Novartis, France; Novartis Pharma, Switzerland


BANBritish Approved Name
BANMBritish Approved Name (Modified)
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.